Published in J Clin Oncol on January 20, 2007
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol (2014) 2.30
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol (2014) 1.43
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol (2009) 1.09
Pure choriocarcinoma of the testis presenting with jaundice: a case report and review of the literature. J Med Case Rep (2012) 0.96
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
The role of high-dose chemotherapy in the treatment of testicular cancer. Open Access J Urol (2010) 0.89
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Br J Cancer (2011) 0.89
High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther (2011) 0.89
Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol (2010) 0.84
Management of poor-prognosis testicular germ cell tumors. Indian J Urol (2010) 0.83
Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol (2010) 0.83
Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol (2012) 0.82
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol (2016) 0.79
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. J Clin Oncol (2015) 0.79
Chemotherapy for patients with poor prognosis germ cell tumors. World J Urol (2009) 0.77
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. Braz J Med Biol Res (2014) 0.76
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol (2016) 0.76
False elevation of human chorionic gonadotropin in a patient with testicular cancer. Nat Rev Urol (2010) 0.75
A Literature Review and Case Report of Metastatic Pure Choriocarcinoma. Case Rep Oncol Med (2015) 0.75
Poor-prognosis germ cell tumors: we have not yet crossed the finish line. J Clin Oncol (2007) 0.75
[Not Available]. Can Urol Assoc J (2014) 0.75
Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. PLoS One (2015) 0.75
Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours? ESMO Open (2016) 0.75
Prognostic factors in children with extracranial germ cell tumors treated with cisplatin-based chemotherapy. Korean J Pediatr (2015) 0.75
High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells (2015) 0.75
Optimal management of testicular cancer: from self-examination to treatment of advanced disease. Open Access J Urol (2010) 0.75
Salvage chemotherapy for metastatic germ cell tumours: The known unknowns. Can Urol Assoc J (2012) 0.75
Urologic oncology: Poor trial accrual hinders germ cell tumor therapy advances. Nat Rev Urol (2012) 0.75
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone Marrow Transplant (2016) 0.75
[What is new in 2011 regarding testicular cancer]. Urologe A (2011) 0.75
Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience. Childs Nerv Syst (2015) 0.75
Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors. J Cancer Res Clin Oncol (2013) 0.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Multiple myeloma. Lancet (2009) 4.60
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology (2009) 3.66
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology (2013) 3.45
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg (2009) 2.93
Aurora kinases as anticancer drug targets. Clin Cancer Res (2008) 2.92
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol (2002) 2.78
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Current applications for prostate-specific antigen doubling time. Eur Urol (2008) 2.76
Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology (2014) 2.73
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol (2008) 2.71
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol (2013) 2.63
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging (1999) 2.43
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 2.42
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol (2002) 2.39
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
A simple algorithm to predict incident kidney disease. Arch Intern Med (2008) 2.36
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol (2003) 2.29
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol (2005) 2.25
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2003) 2.22
Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg (2008) 2.21
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol (2007) 2.20
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Where do patients with cancer in Iowa receive radiation therapy? J Oncol Pract (2014) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Medical treatment of advanced testicular cancer. JAMA (2008) 2.11
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol (2012) 2.10